MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL
5/20/2014 9:43:57 AM
MARTINSRIED / MUNICH, Germany, May 20, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the Food & Drug Association (FDA) has granted orphan drug designation to MOR208, MorphoSys' humanized Fc engineered monoclonal antibody against CD19, for the treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL). Additionally, the Company has received a positive opinion from the European Medicines Agency (EMA) for an orphan medicinal product application for MOR208 in these indications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by